336
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data

ORCID Icon, , , , , & show all
Pages 491-493 | Received 21 Aug 2019, Accepted 18 Sep 2019, Published online: 03 Oct 2019
 

Author contributions

CL and CB performed the research, AKF designed the research, CL and AKF analyzed the data and wrote the paper, REH, AK, CF, DM contributed patient data. All authors read and approved the final version.

Disclosure statement

No potential conflict of interest was reported by the authors.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.